Insider Transactions in Q1 2021 at Opiant Pharmaceuticals, Inc. (OPNT)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 17
2021
|
Gabrielle Alison Silver Director |
SELL
Open market or private sale
|
Direct |
7,157
-30.28%
|
$78,727
$11.07 P/Share
|
|
Mar 17
2021
|
Gabrielle Alison Silver Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,886
+25.02%
|
$78,860
$10.0 P/Share
|
|
Mar 17
2021
|
Ann L. Mac Dougall Director |
SELL
Open market or private sale
|
Direct |
6,606
-24.07%
|
$72,666
$11.07 P/Share
|
|
Mar 17
2021
|
Ann L. Mac Dougall Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,279
+20.96%
|
$72,790
$10.0 P/Share
|
|
Mar 16
2021
|
Gabrielle Alison Silver Director |
SELL
Open market or private sale
|
Direct |
1,949
-11.01%
|
$21,439
$11.5 P/Share
|
|
Mar 16
2021
|
Gabrielle Alison Silver Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,231
+11.19%
|
$22,310
$10.0 P/Share
|
|
Mar 16
2021
|
Ann L. Mac Dougall Director |
SELL
Open market or private sale
|
Direct |
1,949
-8.81%
|
$21,439
$11.5 P/Share
|
|
Mar 16
2021
|
Ann L. Mac Dougall Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,231
+9.16%
|
$22,310
$10.0 P/Share
|
|
Mar 15
2021
|
Gabrielle Alison Silver Director |
SELL
Open market or private sale
|
Direct |
3,900
-20.14%
|
$42,900
$11.64 P/Share
|
|
Mar 15
2021
|
Gabrielle Alison Silver Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,518
+18.92%
|
$45,180
$10.0 P/Share
|
|
Mar 15
2021
|
Ann L. Mac Dougall Director |
SELL
Open market or private sale
|
Direct |
5,600
-21.98%
|
$61,600
$11.63 P/Share
|
|
Mar 15
2021
|
Ann L. Mac Dougall Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,483
+20.28%
|
$64,830
$10.0 P/Share
|
|
Mar 05
2021
|
Gabrielle Alison Silver Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,334
+35.95%
|
$83,340
$10.0 P/Share
|
|
Feb 11
2021
|
Ann L. Mac Dougall Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+26.92%
|
$70,000
$10.0 P/Share
|
|
Jan 26
2021
|
Brian Gorman |
BUY
Grant, award, or other acquisition
|
Direct |
6,774
+14.74%
|
-
|
|
Jan 26
2021
|
Phil Skolnick Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,198
+29.57%
|
-
|
|
Jan 26
2021
|
Mark Jason Heath Ellison Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,636
+45.71%
|
-
|
|
Jan 26
2021
|
David D O'Toole Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,850
+15.48%
|
-
|
|
Jan 26
2021
|
Roger Crystal Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,416
+20.03%
|
-
|